Chemotherapy — Mechanisms and Toxicities

• Alkylating agents (cyclophosphamide, cisplatin, nitrogen mustards): These drugs form covalent cross-links with DNA at the N-7 position of guanine bases. The mechanism involves nucleophilic attack by the electron-rich guanine on the electrophilic alkyl group, creating interstrand and intrastrand DNA cross-links that prevent DNA replication and transcription. In cancer cells, these lesions trigger apoptosis through p53-dependent pathways. However, alkylating agents are non-phase-specific and damage DNA in both dividing and non-dividing cells. The cross-linking capability persists after drug elimination, explaining delayed toxicities such as secondary malignancies and infertility. Cisplatin, a platinum-based alkylator, additionally generates reactive oxygen species (ROS), causing oxidative damage and mitochondrial dysfunction, particularly affecting the proximal renal tubule and sensory ganglia.

• Antimetabolites (methotrexate, 5-fluorouracil, cytarabine, gemcitabine): These agents are incorporated into DNA and RNA or inhibit essential biosynthetic enzymes, predominantly affecting S-phase cells. Methotrexate inhibits dihydrofolate reductase, depleting deoxyribonucleotides and thymidine required for DNA synthesis; 5-fluorouracil is converted to active metabolites that inhibit thymidylate synthase and incorporate into RNA; cytarabine (arabinosylcytosine) is phosphorylated to the active triphosphate form and incorporated into DNA, causing chain termination. These drugs are S-phase specific, causing maximal damage during active DNA replication. Toxicity to rapidly proliferating normal tissues results from the same mechanism: bone marrow depression (myelosuppression), mucositis from epithelial damage, and diarrhea. The biochemical basis of methotrexate's mucositis includes impaired nucleotide synthesis leading to apoptosis of crypt epithelial cells and impaired DNA repair.

• Topoisomerase inhibitors (etoposide, irinotecan, doxorubicin, topotecan): These agents inhibit topoisomerase II (etoposide, doxorubicin) or topoisomerase I (irinotecan, topotecan) enzymes that normally create transient DNA breaks to relieve topological stress during replication and transcription. By stabilizing the cleavage complex (the enzyme-DNA intermediate), chemotherapy converts these normally reversible breaks into permanent, irreparable lesions. During DNA replication, the replication fork collides with stabilized cleavage complexes, converting them to double-strand breaks, which trigger apoptosis in S-phase cells. Topoisomerase II inhibitors are S/G2-phase specific. Doxorubicin additionally intercalates into DNA (inserting between base pairs) and generates ROS through redox cycling with its semiquinone radical form. The ROS generation explains its cardiotoxicity mechanism: oxidative stress in myocardial mitochondria leads to chronic cardiomyopathy. Cumulative lifetime dose is the critical determinant of cardiotoxicity risk.

• Microtubule-targeting agents (taxanes: paclitaxel/docetaxel; vinca alkaloids: vincristine/vinblastine): These drugs disrupt the dynamic equilibrium of microtubule polymerization and depolymerization. Taxanes stabilize microtubules by binding to β-tubulin and preventing depolymerization, whereas vinca alkaloids prevent polymerization by binding to tubulin dimers. Both mechanisms result in arrest of cells in mitosis (M-phase) as the mitotic spindle cannot form or function properly, triggering apoptosis. The M-phase specificity means these agents preferentially target cycling cells. Peripheral neuropathy from microtubule-targeting agents results from direct damage to sensory and motor axons, with the dorsal root ganglia and peripheral sensory nerves particularly vulnerable. Taxane-induced neuropathy involves microtubule disruption within neurons, impaired axonal transport, and mitochondrial dysfunction, leading to axonal degeneration.

• Targeted molecularly-directed agents: Modern chemotherapy includes tyrosine kinase inhibitors (TKIs, e.g., imatinib, erlotinib), monoclonal antibodies (trastuzumab, rituximab), and small-molecule inhibitors targeting specific oncogenic pathways (BRAF inhibitors, PD-L1 checkpoint inhibitors). These exploit oncogenic driver mutations or tumor-associated antigens, theoretically improving selectivity. However, toxicities still occur from off-target effects and from the normal physiologic functions of the targeted proteins. For example, HER2 inhibitors cause cardiotoxicity because HER2 signaling is important for cardiac myocyte survival, and EGFR inhibitors cause rash and diarrhea because EGFR is essential for normal skin and GI epithelial homeostasis.

• Immune-mediated mechanisms and checkpoint inhibitors: Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) release the "brakes" on anti-tumor T-cell immunity by blocking inhibitory signaling pathways. While this enhances anti-tumor immunity, it can lead to loss of self-tolerance and autoimmune-like complications (immune-related adverse events, irAEs). These include colitis, pneumonitis, hepatitis, myocarditis, and thyroiditis. The pathophysiology involves aberrant T-cell activation against self-antigens in the affected organs.

Determinants of chemotherapy toxicity severity

• Drug-specific factors: Each chemotherapeutic agent has characteristic dose-limiting toxicities determined by its mechanism and pharmacokinetics. Alkylating agents and nitrosoureas primarily cause myelosuppression and mucositis; anthracyclines and other topoisomerase inhibitors cause cardiotoxicity; platinum compounds cause nephrotoxicity and neuropathy; taxanes and vinca alkaloids cause peripheral neuropathy. Cumulative lifetime dose is critical for cardiotoxic agents (e.g., doxorubicin >400-550 mg/m² significantly increases cardiomyopathy risk). Drug half-life and clearance mechanisms affect toxicity duration: rapidly cleared agents cause acute toxicities, while agents with long tissue residence times (e.g., some platinum compounds, anthracyclines that bind to tissue) cause delayed or chronic toxicities.

• Patient-related risk factors: Age is a critical determinant; elderly patients (>70 years) have reduced bone marrow reserve, decreased renal and hepatic function, and comorbidities that increase vulnerability to chemotherapy toxicity. Renal dysfunction impairs clearance of drugs and their active metabolites (cisplatin, ifosfamide, high-dose methotrexate), increasing accumulation and toxicity. Hepatic impairment affects metabolism of many drugs (taxanes require hepatic glucuronidation; etoposide undergoes hepatic metabolism). Genetic polymorphisms in drug-metabolizing enzymes (cytochrome P450, dihydropyrimidine dehydrogenase) influence drug activation and clearance; for example, patients with dihydropyrimidine dehydrogenase deficiency experience severe 5-fluorouracil toxicity. Preexisting organ dysfunction (cardiomyopathy, neuropathy, myelosuppression) worsens chemotherapy-related complications. Poor performance status and nutritional status predict worse tolerance.

• Comorbidities and concurrent medications: Diabetes and preexisting peripheral neuropathy increase risk of chemotherapy-induced peripheral neuropathy. Preexisting cardiac disease or left ventricular dysfunction increases cardiotoxicity risk from anthracyclines and trastuzumab. Concomitant use of other cardiotoxic drugs (e.g., trastuzumab with doxorubicin) increases risk synergistically. Renal disease increases toxicity of nephrotoxic agents (cisplatin, ifosfamide). Hepatitis or cirrhosis impairs metabolism of many chemotherapies.

• Treatment-related factors: Higher cumulative doses increase toxicity risk across all drug classes. Accelerated or dose-dense scheduling increases acute toxicities. Combination chemotherapy regimens increase toxicity compared to single-agent therapy. Prior chemotherapy or radiation to specific organs (e.g., prior chest radiation increases cardiotoxicity risk from anthracyclines). The sequence of drug administration can matter: for example, doxorubicin before paclitaxel may increase cardiotoxicity compared to reverse sequence.

• Demographic factors: Women may experience greater severity of certain toxicities (e.g., cardiotoxicity from anthracyclines). Younger patients may experience different toxicity spectra (e.g., greater fertility concerns with alkylating agents). Body surface area affects dosing and toxicity; underweight patients may have excessive drug concentrations, while obese patients may require dose adjustments.

Acute toxicities (occurring during or within days to weeks of treatment)

• Bone marrow suppression (myelosuppression): Results from direct cytotoxic damage to hematopoietic progenitor cells in the bone marrow. Chemotherapy induces apoptosis of rapidly dividing myeloid and erythroid precursors. The nadir (lowest blood counts) typically occurs 7-14 days after drug administration for most agents, though some (e.g., nitrosoureas) have delayed nadirs at 3-6 weeks. Neutropenia (absolute neutrophil count <1500/μL, severe <500/μL) increases infection risk; patients present with fever, chills, localized infections (pneumonia, urinary tract infection, skin infections). Thrombocytopenia (<50,000/μL) causes spontaneous bleeding, petechiae, and mucosal hemorrhage. Anemia causes fatigue, dyspnea, and tachycardia. The risk of infections is proportional to the depth and duration of neutropenia; patients with neutrophil counts <100/μL for >7 days are at very high risk for serious infections including sepsis and opportunistic infections.

• Mucositis (stomatitis): Chemotherapy damages the rapidly proliferating basal epithelial cells of the gastrointestinal mucosa. Ulceration begins 3-7 days after drug administration, starting with erythema and progressing to painful ulceration of the oral mucosa, pharynx, and throughout the GI tract. Patients report severe oral pain, difficulty eating and swallowing (dysphagia), and increased salivation. Secondary bacterial or candidal infections are common. Severe mucositis requires parenteral nutrition or feeding tubes. The pathophysiology involves direct cytotoxic injury, subsequent inflammatory response, and microbial superinfection.

• Nausea and vomiting: Chemotherapy triggers nausea and vomiting through multiple mechanisms: direct irritation of the gastric mucosa, stimulation of the chemoreceptor trigger zone (CTZ) in the area postrema outside the blood-brain barrier (particularly by highly emetogenic agents like cisplatin and anthracyclines), and vagal afferent signaling from the GI tract (particularly from agents causing mucositis). The severity depends on drug, dose, and individual susceptibility. Acute emesis occurs within 24 hours; delayed emesis (24 hours to several days) results from sustained CTZ stimulation and mucosal damage. Severe vomiting causes dehydration, electrolyte abnormalities (hypokalemia, hyponatremia), and esophageal injury.

• Hypersensitivity reactions: Some chemotherapies, particularly taxanes (paclitaxel, docetaxel) and platinum compounds (cisplatin, carboplatin), cause infusion reactions. These result from direct mast cell and basophil degranulation or complement activation. Reactions present as urticaria, flushing, dyspnea, hypotension, chest pain, and rarely anaphylaxis. Taxanes require premedication with antihistamines and corticosteroids. Platinum agents are associated with cumulative hypersensitivity risk, increasing after prior doses.

• Alopecia: Chemotherapy damages hair follicle matrix cells, causing hair loss. This is reversible but psychologically distressing. All agents can cause alopecia to varying degrees; taxanes, anthracyclines, and alkylating agents are particularly likely to cause complete scalp alopecia.

• Diarrhea and constipation: Direct cytotoxic damage to the intestinal epithelium causes diarrhea, particularly with antimetabolites and topoisomerase inhibitors. Irinotecan is particularly associated with severe diarrhea through both direct mucosal damage and delayed effects mediated by intestinal bacterial β-glucuronidase. Severity ranges from mild to life-threatening (severe dehydration, electrolyte losses). Paradoxically, some agents (particularly vinca alkaloids and higher-dose opioids used for pain control) cause constipation through reduced gut motility.

Subacute to chronic toxicities

• Peripheral neuropathy: Taxanes, vinca alkaloids, platinum compounds, and proteasome inhibitors cause dose-dependent peripheral neuropathy. The mechanism involves direct axonal damage, impaired microtubule function (for microtubule-targeting agents), and mitochondrial dysfunction. Patients develop progressive paresthesias (numbness and tingling) in a stocking-glove distribution, starting distally in the lower extremities and progressing proximally with continued treatment. Sensory neuropathy predominates, though motor involvement can occur. Chemotherapy-induced peripheral neuropathy (CIPN) is often dose-limiting and can be irreversible, persisting months to years after treatment completion. Pain, loss of proprioception, and weakness impair function and quality of life.

• Cardiotoxicity: Anthracyclines, some targeted agents (HER2 inhibitors like trastuzumab), and checkpoint inhibitors cause cardiotoxicity through distinct mechanisms. Anthracycline-induced cardiomyopathy results from cumulative ROS-mediated oxidative stress leading to myocardial apoptosis, mitochondrial dysfunction, and myofibril damage. This is dose-dependent (increased risk with cumulative doxorubicin >400-550 mg/m²) and can manifest as acute myocarditis (during or shortly after treatment) or chronic dilated cardiomyopathy (months to years later). Patients develop dyspnea, orthopnea, edema, and fatigue from reduced ejection fraction. Trastuzumab causes reversible left ventricular dysfunction through HER2 pathway inhibition in cardiomyocytes; this is less often fatal than anthracycline cardiotoxicity but requires monitoring. Checkpoint inhibitors can cause myocarditis presenting as chest pain, dyspnea, arrhythmias, and fulminant heart failure.

• Nephrotoxicity: Platinum compounds (cisplatin, oxaliplatin) and high-dose methotrexate cause direct renal tubular toxicity. Cisplatin is the most nephrotoxic, causing acute tubular necrosis predominantly affecting the proximal tubule. Patients develop rising serum creatinine, electrolyte wasting (magnesium, potassium, calcium), and sometimes acute kidney injury. The mechanism involves platinum accumulation in tubular cells, mitochondrial dysfunction, and ROS generation. Adequate hydration and diuresis reduce nephrotoxicity. Long-term sequelae include chronic kidney disease and electrolyte abnormalities.

• Ototoxicity: Cisplatin causes irreversible ototoxicity through damage to cochlear hair cells. High-frequency hearing loss occurs first, progressing to lower frequencies with continued dosing. Cumulative dose and higher individual doses increase risk. Patients report tinnitus and progressive hearing loss

Organ-specific toxicities with antidotes

• Cyclophosphamide/ifosfamide — hemorrhagic cystitis: the metabolite acrolein is urotoxic to bladder urothelium. Prevent with aggressive hydration and mesna, a sulfhydryl donor that conjugates acrolein in urine. Ifosfamide may also cause encephalopathy (chloroacetaldehyde); methylene blue has been used, though evidence is anecdotal. Cyclophosphamide can cause SIADH.
• Methotrexate: mucositis, myelosuppression, hepatotoxicity, and crystal nephropathy from precipitation in acidic tubular fluid — prevent with hydration and urinary alkalinization. Leucovorin (folinic acid) rescue bypasses dihydrofolate reductase; glucarpidase cleaves circulating methotrexate when clearance is delayed with renal injury. Avoid NSAIDs, penicillins, and probenecid (reduce tubular secretion); third-space fluid (ascites, effusion) prolongs exposure. Contraindicated in pregnancy (abortifacient/teratogen).
• 5-Fluorouracil/capecitabine: myelosuppression, diarrhea, palmar-plantar erythrodysesthesia, and coronary vasospasm. Severe toxicity occurs with dihydropyrimidine dehydrogenase (DPYD) deficiency; the FDA-approved reversal agent for overdose or early severe toxicity is uridine triacetate. Leucovorin potentiates 5-FU and is not an antidote.
• Anthracyclines: cumulative, largely irreversible dilated cardiomyopathy from iron-dependent ROS injury. Dexrazoxane, an iron-chelating/topoisomerase-II-modulating agent, is used for cardioprotection and for extravasation. ASCO and ACC/AHA cardio-oncology guidance support baseline and serial LVEF assessment (echo or MUGA) in patients receiving anthracyclines or trastuzumab; trastuzumab-related dysfunction is usually reversible with drug interruption.
• Cisplatin: acute tubular necrosis with magnesium and potassium wasting, and irreversible high-frequency ototoxicity — monitor creatinine, electrolytes, and audiometry; amifostine is an approved cytoprotectant. Saline hydration ± forced diuresis is standard; substitute carboplatin when nephrotoxicity limits therapy.
• Bleomycin: pulmonary fibrosis from ROS in lung tissue lacking bleomycin hydrolase. Monitor DLCO/PFTs; avoid high FiO₂ and cumulative dosing.
• Vincristine: dose-limiting peripheral and autonomic neuropathy; it is fatal if given intrathecally and must be dispensed only in a minibag for IV use.
• Irinotecan: early cholinergic diarrhea (treat with atropine) and late secretory diarrhea (high-dose loperamide); *UGT1A1\*28* homozygotes are at higher risk of neutropenia.
• Checkpoint inhibitors: immune-related colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, myocarditis. Per ASCO/NCCN immunotherapy toxicity guidance, hold the drug and give systemic corticosteroids for moderate-to-severe events.

• Hemorrhagic cystitis after cyclophosphamide: the answer is acrolein, and the single best next step is hydration plus mesna. Distractor to avoid: mesna does not prevent myelosuppression or secondary bladder cancer risk.
• High-dose methotrexate toxicity: give leucovorin rescue; if clearance is delayed with acute kidney injury, add glucarpidase. Reflex trap: leucovorin worsens 5-fluorouracil toxicity — the 5-FU antidote is uridine triacetate, and the underlying lesion is DPD (DPYD) deficiency.
• Doxorubicin = dose-dependent dilated cardiomyopathy from free-radical injury; dexrazoxane is the cardioprotectant. Contrast with trastuzumab, which causes LVEF decline that is generally reversible and not strictly cumulative-dose dependent. Both require baseline and serial LVEF per ASCO/ACC guidance.
• Cisplatin = nephrotoxicity + ototoxicity + peripheral neuropathy + severe emesis; monitor magnesium (renal wasting) and get audiometry. Carboplatin swaps that profile for myelosuppression (thrombocytopenia).
• Vincristine hits nerves; vinblastine "blasts" the marrow. The board-tested catastrophe is intrathecal vincristine, which is uniformly fatal — it is IV only.
• Bleomycin and busulfan → pulmonary fibrosis; bleomycin causes no significant myelosuppression, and supplemental oxygen amplifies lung injury. Monitor DLCO.
• Cytarabine at high dose causes cerebellar ataxia and chemical conjunctivitis (prophylactic steroid eye drops); etoposide and alkylators cause secondary leukemias — topoisomerase II inhibitors classically with KMT2A/MLL (11q23) rearrangement and a short latency, alkylators with a longer latency and chromosome 5/7 deletions.
• Fever plus ANC <500/μL is a medical emergency: per IDSA, obtain cultures and start empiric antipseudomonal beta-lactam monotherapy (cefepime, piperacillin-tazobactam, or a carbapenem) without waiting for a source. Do not delay antibiotics for imaging, and do not add vancomycin reflexively — reserve it for suspected line infection, skin/soft tissue source, hemodynamic instability, or known MRSA colonization.